Retatrutide 20mg

Mechanism

Retatrutide is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. In vitro it activates all three receptors with sub-nanomolar potency in cAMP-accumulation assays, with characterized bias profiles distinct from dual-agonist Tirzepatide.

In-vitro applications

• GLP-1/GIP/glucagon receptor signaling
  cAMP accumulation + β-arrestin recruitment assays in CHO cells stably expressing each receptor.
  Working range: pM to nM range
• Adipocyte lipolysis modeling
  Comparative lipolysis assays in 3T3-L1 differentiated adipocytes vs Tirzepatide.
  Working range: 1 nM to 100 nM
• Hepatic energy expenditure
  Mitochondrial respiration (Seahorse XF) measurements in HepG2 hepatocytes.
  Working range: 10 nM to 1 µM

Researchers commonly co-treat with

• [[Tirzepatide]] — Side-by-side dual vs triple agonist comparison in receptor activation panels.
• [[Semaglutide]] — Single-agonist baseline for receptor-bias and ligand-residency studies.

Storage and handling

• · Lyophilized: −20°C or below, desiccated
• · Reconstituted: 2–8°C, use within 30 days
• · Light + air: Protect from light and air
• · Solubility: Soluble in bacteriostatic water (0.9% benzyl alcohol)

See also: [[lyophilization]] · [[reconstitution]]

Selected peer-reviewed citations

1. Coskun T, et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metabolism.
2. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine.

Bundled in stacks

• · [[Recomp Elite]] — $259.97
• · [[The Flagship — Aurex Elite]] — $1,299.97